Profile data is unavailable for this security.
About the company
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
- Revenue in USD (TTM)2.72m
- Net income in USD-85.08m
- Incorporated2016
- Employees75.00
- LocationShattuck Labs Inc500 W. 5Th Street, Suite 100AUSTIN 78701United StatesUSA
- Phone+1 (512) 900-4690
- Websitehttps://www.shattucklabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xeris Biopharma Holdings Inc | 171.36m | -64.40m | 334.32m | 377.00 | -- | -- | -- | 1.95 | -0.4648 | -0.4648 | 1.24 | -0.0619 | 0.5209 | 0.838 | 5.02 | 454,525.20 | -19.58 | -43.60 | -25.58 | -56.57 | 82.90 | 78.23 | -37.58 | -143.08 | 1.81 | -2.04 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
Zura Bio Ltd | 0.00 | -60.18m | 334.34m | 14.00 | -- | 3.75 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Ventyx Biosciences Inc | 0.00 | -192.60m | 336.99m | 74.00 | -- | 1.10 | -- | -- | -3.24 | -3.24 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -53.41 | -- | -55.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
Nautilus Biotechnology Inc | 0.00 | -67.44m | 343.23m | 163.00 | -- | 1.38 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Anavex Life Sciences Corp | 0.00 | -40.59m | 343.64m | 40.00 | -- | 2.52 | -- | -- | -0.4962 | -0.4962 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -26.73 | -40.04 | -28.98 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
C4 Therapeutics Inc | 20.04m | -126.07m | 344.03m | 145.00 | -- | 1.33 | -- | 17.17 | -2.37 | -2.37 | 0.3677 | 3.76 | 0.0504 | -- | 2.84 | 138,179.30 | -31.74 | -25.91 | -36.02 | -29.45 | -- | -- | -629.24 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
Sutro Biopharma Inc | 154.07m | -114.96m | 345.58m | 300.00 | -- | 2.69 | -- | 2.24 | -1.89 | -1.89 | 2.53 | 1.57 | 0.4047 | -- | 7.48 | 510,149.00 | -30.20 | -25.48 | -36.94 | -29.75 | -- | -- | -74.62 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
OraSure Technologies, Inc. | 304.64m | 22.85m | 349.83m | 638.00 | 15.56 | 0.8207 | 8.17 | 1.15 | 0.304 | 0.304 | 4.11 | 5.76 | 0.6573 | 2.77 | 4.31 | 477,493.70 | 4.93 | 0.7238 | 5.42 | 0.8212 | 45.26 | 46.94 | 7.50 | 1.13 | 10.49 | -- | 0.0017 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
Shattuck Labs Inc | 2.72m | -85.08m | 350.93m | 75.00 | -- | 2.72 | -- | 129.25 | -1.93 | -1.93 | 0.0608 | 2.71 | 0.0168 | -- | -- | 36,200.00 | -52.52 | -29.14 | -57.94 | -32.42 | -- | -- | -3,133.63 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
Tourmaline Bio Inc | 0.00 | -32.94m | 353.15m | 44.00 | -- | 0.9972 | -- | -- | -5.35 | -5.35 | 0.00 | 13.81 | 0.00 | -- | -- | 0.00 | -12.39 | -- | -12.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Precigen Inc | 5.44m | -96.91m | 353.39m | 202.00 | -- | 3.61 | -- | 64.97 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
Amarin Corporation plc (ADR) | 277.46m | -52.61m | 355.40m | 275.00 | -- | 0.6508 | -- | 1.28 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
Cibus Inc | 2.32m | -285.67m | 356.99m | 183.00 | -- | 1.09 | -- | 153.87 | -18.29 | -18.29 | 0.1522 | 13.24 | 0.0084 | -- | -- | 12,677.60 | -129.84 | -86.28 | -147.90 | -96.45 | -- | -- | -15,483.49 | -792.07 | -- | -3.17 | 0.0039 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
Verrica Pharmaceuticals Inc | 8.91m | -80.74m | 360.99m | 100.00 | -- | 239.39 | -- | 40.50 | -1.75 | -1.75 | 0.1929 | 0.0356 | 0.1321 | -- | 2.33 | 89,130.00 | -119.66 | -55.75 | -142.98 | -78.33 | 79.63 | -- | -905.83 | -754.94 | 3.04 | -21.71 | 0.9678 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
Aura Biosciences Inc | 0.00 | -78.65m | 364.14m | 88.00 | -- | 1.74 | -- | -- | -1.86 | -1.86 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -35.66 | -- | -37.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
Organogenesis Holdings Inc | 435.47m | 5.82m | 364.57m | 862.00 | 63.25 | 1.31 | 17.17 | 0.8372 | 0.0435 | 0.0435 | 3.28 | 2.11 | 0.9628 | 4.08 | 4.63 | 505,190.30 | 1.29 | 5.46 | 1.56 | 6.90 | 75.07 | 74.94 | 1.34 | 4.81 | 2.41 | 8.78 | 0.1955 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 7.12m | 14.97% |
Redmile Group LLCas of 31 Mar 2024 | 5.62m | 11.81% |
Prosight Management LPas of 31 Mar 2024 | 3.73m | 7.83% |
Adage Capital Management LPas of 31 Mar 2024 | 2.37m | 4.98% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.81m | 3.80% |
Franklin Advisers, Inc.as of 31 Mar 2024 | 1.66m | 3.50% |
The Clark Estates, Inc.as of 31 Mar 2024 | 1.48m | 3.10% |
Laurion Capital Management LPas of 31 Mar 2024 | 661.04k | 1.39% |
Millennium Management LLCas of 31 Mar 2024 | 612.38k | 1.29% |
Pinnacle Associates Ltd.as of 31 Mar 2024 | 521.25k | 1.10% |